Zeng B-Y, Iravani M M, Lin S-T, Irifune M, Kuoppamäki M, Al-Barghouthy G, Smith L, Jackson M J, Rose S, Medhurst A D, Jenner P
Neurodegenerative Disease Research Group, GKT School of Biomedical and Health Sciences, King's College, London, SE1 1UL, UK.
Eur J Neurosci. 2006 Apr;23(7):1766-74. doi: 10.1111/j.1460-9568.2006.04718.x.
Dysfunction of the ubiquitin-proteasome system occurs in the substantia nigra (SN) in Parkinson's disease (PD). However, it is unknown whether this is a primary cause or a secondary consequence of other components of the pathogenic process. We have investigated in nonhuman primates whether initiating cell death through mitochondrial complex I inhibition using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) altered proteasomal activity or the proteasomal components in the SN. Chymotrypsin-like, trypsin-like and peptidylglutamyl-peptide hydrolase (PGPH) activating of 20S proteasome were decreased in SN homogenates of MPTP-treated marmosets compared to naïve animals. Western blotting revealed a marked decrease in the expression of 20S-alpha subunits, but no change in 20S-beta subunits in the SN of MPTP-treated marmoset compared to naïve animals. There was a marked decrease in the expression of the proteasome activator 700 (PA700) and proteasome activator 28 (PA28) regulatory complexes. The 20S-alpha4 subunit immunoreactivity was decreased in the nucleus of colocalized tyrosine hydroxylase (TH)-positive cells of MPTP-treated animals compared to naïve animals but no difference in the intensity of 20S-beta1i subunit staining. Immunoreactivity for PA700-Rpt5 and PA28-alpha subunits within surviving TH-positive cells of MPTP-treated marmoset was reduced compared to naïve controls. Overall, the changes in proteasomal function and structure occurring follow MPTP-induced destruction of the SN in common marmosets were very similar to those found in PD. This suggests that altered proteasomal function in PD could be a consequence of other pathogenic processes occurring in SN as opposed to initiating cell death as previously suggested.
帕金森病(PD)中,黑质(SN)会出现泛素 - 蛋白酶体系统功能障碍。然而,这是致病过程中其他成分的主要原因还是次要后果尚不清楚。我们在非人类灵长类动物中研究了使用盐酸1 - 甲基 - 4 - 苯基 - 1,2,3,6 - 四氢吡啶(MPTP)通过抑制线粒体复合体I引发细胞死亡是否会改变SN中的蛋白酶体活性或蛋白酶体成分。与未处理的动物相比,MPTP处理的狨猴SN匀浆中20S蛋白酶体的类胰凝乳蛋白酶样、类胰蛋白酶样和肽基谷氨酰肽水解酶(PGPH)活性降低。蛋白质印迹法显示,与未处理的动物相比,MPTP处理的狨猴SN中20S - α亚基的表达明显降低,但20S - β亚基没有变化。蛋白酶体激活剂700(PA700)和蛋白酶体激活剂28(PA28)调节复合体的表达明显降低。与未处理的动物相比,MPTP处理动物的酪氨酸羟化酶(TH)阳性共定位细胞的细胞核中20S - α4亚基免疫反应性降低,但20S - β1i亚基染色强度没有差异。与未处理的对照相比,MPTP处理的狨猴存活的TH阳性细胞内PA700 - Rpt5和PA28 - α亚基的免疫反应性降低。总体而言,普通狨猴中MPTP诱导的SN破坏后发生的蛋白酶体功能和结构变化与PD中发现的变化非常相似。这表明PD中蛋白酶体功能改变可能是SN中发生的其他致病过程的结果,而不是如先前所认为的引发细胞死亡。